ATXI · Avenue Therapeutics, Inc.
What's happening
- ATXI is down 50.37% today, trading at $0.42. — Live quote
- Volume today (10,219) is running 1.7x its 3-month average. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2025-05-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-08-07; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -87.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ATXI
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | $0 | $1.4M | — | $0 | $0 | — |
| Operating income | -$707.0K | -$714.0K | -$724.0K | $297.0K | -$1.9M | -$3.2M | -$2.8M | -$3.7M |
| Net income | -$690.0K | -$695.0K | -$683.0K | $335.0K | -$1.9M | -$3.1M | -$2.7M | -$4.3M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| EPS (basic) | $-0.21 | $-0.21 | $-0.21 | $0.11 | $-0.62 | $-1.92 | $-6.43 | $-15.40 |
| Operating margin | — | — | — | $21 | — | — | — | — |
| Net margin | — | — | — | $24 | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $2.0M | $2.5M | $2.9M | $3.7M | $4.2M | $3.6M | $2.7M | $2.6M |
| Total liabilities | $1.4M | $1.3M | $1.1M | $1.4M | $1.3M | $1.3M | $816.0K | $973.0K |
| Stockholders' equity | $569.0K | $1.2M | $1.8M | $3.6M | $4.1M | $3.5M | $2.8M | $2.6M |
| Total current assets | — | — | — | — | — | — | — | — |
| Total current liabilities | $1.4M | $1.3M | $1.1M | $1.4M | $1.3M | $1.3M | $816.0K | $973.0K |
| Cash & equivalents | $1.9M | $2.4M | $2.9M | $3.7M | $3.3M | $3.5M | $2.6M | $2.6M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts payable | — | — | — | — | — | — | $155.0K | — |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | -$106.9M | -$106.2M | -$105.5M | -$104.8M | -$104.1M | -$104.4M | -$102.6M | -$101.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$475.0K | -$438.0K | -$854.0K | $383.0K | -$176.0K | -$1.2M | -$764.0K | -$2.9M |
| Investing cash flow | — | — | — | — | — | — | $0 | $0 |
| Financing cash flow | $0 | $0 | $0 | $0 | $0 | $2.1M | $761.0K | $567.0K |
| Share-based compensation | $61.0K | $61.0K | $142.0K | $163.0K | $175.0K | $185.0K | $522.0K | $331.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $1.4M | $0 | — | — | — |
| Operating income | -$3.1M | -$11.3M | -$14.5M | -$8.0M | -$3.7M |
| Net income | -$2.9M | -$11.7M | — | -$3.6M | -$3.7M |
| EPS (diluted) | — | — | — | — | $-0.22 |
| EPS (basic) | $-0.93 | $-15.79 | $-73.48 | $-1.63 | $-0.22 |
| Operating margin | -$220 | — | — | — | — |
| Net margin | -$207 | — | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $2.9M | $2.7M | $1.9M | $6.8M | $4.0M |
| Total liabilities | $1.1M | $816.0K | $1.2M | $3.6M | $509.0K |
| Stockholders' equity | $1.8M | $2.8M | $1.6M | $3.9M | $3.5M |
| Total current assets | — | — | — | — | $4.0M |
| Total current liabilities | $1.1M | $816.0K | $1.2M | $3.6M | $509.0K |
| Cash & equivalents | $2.9M | $2.6M | $1.8M | $6.7M | $3.8M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts payable | — | $155.0K | $78.0K | $129.0K | $304.0K |
| Common stock & paid-in capital | $0 | $0 | $3.0K | $0 | $2.0K |
| Retained earnings | -$105.5M | -$102.6M | -$90.9M | -$80.6M | -$77.0M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$1.8M | -$9.0M | -$9.5M | -$7.6M | -$3.8M |
| Investing cash flow | — | $0 | -$3.0M | $0 | — |
| Financing cash flow | $2.1M | $9.8M | $7.5M | $10.5M | $4.4M |
| Share-based compensation | $665.0K | $1.2M | $906.0K | $649.0K | $442.0K |
| Purchases of investments | — | — | — | — | — |
| Share repurchases | — | — | $0 | $1.1M | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ATXI as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-03-31 to 2026-01-02
Recent transactions
- Most recent: Fortress Biotech, Inc. (Reporting person) — Grant / award of 111,209 shares on 2026-01-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Fortress Biotech, Inc. | Reporting person | Grant / award | 2026-01-02 | 111,209 |
| Herskowitz Neil | Director | Open market sale | 2024-12-02 | 23 |
| KRANZLER JAY D | Director | Open market sale | 2024-11-05 | 61 |
| MacLean Alexandra | Chief Executive Officer | Grant / award | 2024-09-23 | 170,000 |
| Jin David | Interim PFO and COO | Grant / award | 2024-09-23 | 65,000 |
| Davidow Robert L | 10% owner | Open market sale | 2023-12-11 | 264,000 |
| ROSENWALD LINDSAY A MD | Director | Open market purchase | 2023-09-08 | 348,675 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-01-02 | Fortress Biotech, Inc. | Reporting person | Grant / award | 111,209 | $0.00 |
| 2025-03-31 | Fortress Biotech, Inc. | Reporting person | Grant / award | 33,724 | $0.00 |
| 2024-12-02 | Herskowitz Neil | Director | Open market sale | 23 | $2.00 |
| 2024-11-05 | KRANZLER JAY D | Director | Open market sale | 61 | $2.24 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:36 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-05-08 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-03-30 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-02-23 | 8-K | 2026-02-18 | View on SEC.gov → |
| 2026-01-06 | 4 | 2026-01-02 | View on SEC.gov → |
| 2025-12-31 | 8-K | 2025-12-30 | View on SEC.gov → |
| 2025-11-18 | 8-K | 2025-11-14 | View on SEC.gov → |
| 2025-11-13 | 10-Q | 2025-09-30 | View on SEC.gov → |
| 2025-11-12 | 8-K | 2025-11-05 | View on SEC.gov → |
| 2025-08-14 | 10-Q | 2025-06-30 | View on SEC.gov → |
| 2025-05-15 | 10-Q | 2025-03-31 | View on SEC.gov → |
| 2025-04-30 | 8-K | 2025-04-24 | View on SEC.gov → |
Recent news
Headlines about ATXI (Avenue Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
Yahoo Finance · 2026-02-23 -
Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics
Seeking Alpha · 2025-11-06 -
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
Yahoo Finance · 2025-11-06 -
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
Yahoo Finance · 2025-11-06
No headlines in this category right now — try “All”.